Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.

Investing.com -- Moderna , Inc. (NASDAQ: MRNA) shares surged 14% following remarks by Oracle (NYSE: ORCL) Chairman Larry ...

U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially ...

The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to ...

Now, it’s worth noting Stock Advisor’s total average return is 894% — a market-crushing outperformance compared to 176% for ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

A population-based congenital cytomegalovirus screening program in Ontario successfully screened 551,034 newborns; of those ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Netflix earnings after the bell drive focus in tech stocks. Dow and S&P climb as optimism over trade policy fuels market ...